Posted by Michael Wonder on 23 May 2021
Congress loves a big pharma villain. But will that lead to any real policy changes on drug prices?
21 May 2021 - There's a funny cycle that resurfaces every now and then within the life sciences industry.
A particularly odious actor arises that's pretty easy to turn into a boogeyman (see: Martin Shkreli, or the company that used to be known as Valeant Pharmaceuticals).
What some might call clear price-gouging tactics by such entities make for a convenient, and politically bipartisan, punching bag as a sort-of synecdoche of the sector's moral failings.
